Lilly Endowment Inc, an insider of Eli Lilly and Co (LLY), executed a significant sale of 93,250,830 shares on November 11, 2025, at a price of $1,011.18 per share. This transaction totals approximately $94.3 billion.
Following the sale, Lilly Endowment Inc retains 93,250,830 shares of the company. Eli Lilly, headquartered in Indianapolis, Indiana, operates within the pharmaceuticals industry, employing 47,000 full-time staff. The company's portfolio includes products for cardiometabolic health, oncology, immunology, and neuroscience.
Eli Lilly has a market capitalization of $962.2 billion and a price-to-earnings ratio of 52.26, with earnings per share of 20.45. The company is scheduled to report earnings on August 4, 2026, with an estimated EPS of $7.70 and revenue expectations of $17.9 billion.
Insider transactions are reported to the SEC and can provide insight into executives' perspectives on their stock. However, such activities should be considered alongside other fundamental and technical factors, as they may reflect personal financial strategies rather than company outlooks.